The undersecretary of Prevention and Health Promotion, Hugo López Gatellreported that the Federal Commission for Protection against Sanitary Risks (Cofepris), adopted three of the four clinical trials-to-door to test treatments to help fight the COVID-19.
In a press conference, explained that the first consists in the use of Remdesivir, an antiviral drug that until now has been little used in the world but that, according to preliminary research, may to combat the novel coronavirus.
The second, outlined above, is of a randomized, controlled clinical trial on the drug Tocilizumab, a monoclonal antibody that blocks one of the mechanisms that produces the inflammation of the lung tissue.
While the third assay is based on the hydroxychloroquine, a drug used to treat malaria and rheumatic diseases, and for which there is preliminary evidence of its potential against the COVID-19.
The latter, he added, is the chloroquine in combination with an antibiotic of wide use, called azithromycin.
López Gatell noted that in all cases, we have to ensure that will not be harmful for use in people, and there are international standards that care for the protection of human beings and the quality of the research.
He added that these essays are the product of the collaboration of researchers from various institutions, in particular of the National Institutes of Health of the united States, with whom he has had collaboration.